Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q8WWY3
UPID:
PRP31_HUMAN
Alternative names:
Pre-mRNA-processing factor 31; Serologically defined breast cancer antigen NY-BR-99; U4/U6 snRNP 61 kDa protein
Alternative UPACC:
Q8WWY3; E7ESA8; F1T0A4; F1T0A5; Q17RB4; Q8N7F9; Q9H271; Q9Y439
Background:
U4/U6 small nuclear ribonucleoprotein Prp31, also known as Pre-mRNA-processing factor 31 and Serologically defined breast cancer antigen NY-BR-99, plays a crucial role in pre-mRNA splicing as part of the spliceosome. It is essential for the assembly of the U4/U5/U6 tri-snRNP complex, a key component of the spliceosome machinery.
Therapeutic significance:
The protein's involvement in Retinitis pigmentosa 11, a retinal dystrophy characterized by loss of vision, highlights its potential as a target for therapeutic intervention. Understanding the role of U4/U6 small nuclear ribonucleoprotein Prp31 could open doors to potential therapeutic strategies.